Sign in with Google
bearish
EBOS Group - Fulfilled the Order—Down to NEUTRAL
We downgrade our rating on EBOS Group (EBO) to NEUTRAL from OUTPERFORM on valuation grounds. The recent Pharmaceutical Wholesaler Agreement (PWA) has driven a re-rating in EBO's share price.
What is covered in the Full Insight:
- Introduction
- Valuation and Rating Downgrade
- Earnings and Target Price Update
- Market Pricing and Comparisons
- Outlook and Upcoming Results
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 13-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Toyota Industries (6201 JP): Thoughts on Intrinsic Value
- Foshan Haitian Flavouring & Food (3288 HK): Offering Details & Index Inclusion
- Virgin Australia (VGN AU): Touch & Go for Index Inclusion
- Kioxia IPO Lockup Expiry - US$6.7bn Release, with Shareholders Eager to Sell
- MINISO (9896 HK)'s (Possible) TOP TOY Spin-Off Is Priced In
Top Unpaywalled Insights
More »- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
Discussions
(Paid Plans Only)
Forsyth Barr
New Zealand Professional Investment Services Firm
Price Chart(Sign Up to Access)
- Loading...
x